Quality of Life Amongst Adolescents and Young Adults with Cystic Fibrosis: Correlations with Clinical Outcomes
Overview
Affiliations
Objectives: The current study sought to evaluate the quality of life of young patients with cystic fibrosis and correlate these results with the clinical parameters indicative of disease severity.
Methods: This cross-sectional study applied the validated Portuguese version of a cystic fibrosis specific quality of life questionnaire to clinically stable patients aged 14 to 21 years old. The correlations between the questionnaire domain scores and forced expiratory volume in one second (FEV1) values, the Shwachman-Kulczycki score, and body mass index were assessed, and correlations were considered as significant when p<0.05.
Results: A total of 31 patients (11 females; 16.4±2.3 years old) were evaluated, and the median scores on the questionnaire domains ranged from 66.7 to 100. A significant correlation was found between body mass index and the weight (r=0.43, p=0.016) and the eating questionnaire domains (r=0.44, p=0.013); between FEV1 and the physical (r=0.53, p=0.002) and treatment burden (r=0.41, p=0.023) domains; and between the Shwachman-Kulczycki score and the physical (r=0.39, p=0.03), health (r=0.41, p=0.023), and role (r=0.37, p=0.041) domains. A significant difference was found amongst patients with FEV1 values above or below 60% of the predicted value with regard to the role and health domains. No differences in the scores were found according to gender.
Conclusions: The current cystic fibrosis specific quality of life questionnaire scores exhibited wide variability across all domains; however, they indicated a relatively satisfactory quality of life amongst the patients studied. Certain domains exhibited significant correlations with clinical parameters; thus, this instrument has consistent associations with clinical outcomes.
Tools used to measure quality of life in adults with cystic fibrosis- a systematic review.
Snop-Perkowska D, Switalski J, Wnuk K, Olszewski P, Augustynowicz A Health Qual Life Outcomes. 2025; 23(1):10.
PMID: 39901267 PMC: 11792344. DOI: 10.1186/s12955-025-02338-2.
Humaj-Grysztar M, Rachel M, Bonior J Healthcare (Basel). 2024; 12(12).
PMID: 38921297 PMC: 11204049. DOI: 10.3390/healthcare12121183.
Acceptability of patient reported outcome measures (PROMs) in a cystic fibrosis data registry.
Ratnayake I, Ahern S, Ruseckaite R BMJ Open Respir Res. 2021; 8(1).
PMID: 34281916 PMC: 8291302. DOI: 10.1136/bmjresp-2021-000927.
A systematic review of patient-reported outcome measures (PROMs) in cystic fibrosis.
Ratnayake I, Ahern S, Ruseckaite R BMJ Open. 2020; 10(10):e033867.
PMID: 33004381 PMC: 7534676. DOI: 10.1136/bmjopen-2019-033867.
Gold L, Patrick D, Hansen R, Goss C, Kessler L J Cyst Fibros. 2019; 18(6):886-893.
PMID: 31126901 PMC: 6868291. DOI: 10.1016/j.jcf.2019.05.009.